Cleveland BioLabs, Inc. (Nasdaq: CBLI): Ready to move higher? Print E-mail
By M.E.Garza   
Wednesday, 24 February 2010 08:01

Yesterday, we alerted our subscribers to Cleveland BioLabs, Inc.(NasdaqCM: CBLI). The company announced earlier this week that it will hold a press conference today and while the stock has already seen some gains, it may be poised to move higher.

Already Cleveland BioLabs, Inc. (Nasdaq:CBLI) stock has seen some gains during the last two trading sessions, but I wanted to put it on everyone's watch list because after the company hosts it's Press Conference on Radiation Countermeasure Developments for National Security and Oncologic Safety today -February 24, 2010, 12:30 pm EST-  in New York, there is a feeling among analysts that the stock may begin trading at higher levels in the days and weeks ahead. CBLI traded as high as $6 last July and seems to trade in a very nice range as you look at their chart.

One reason for optimism among speculators is the chatter that several countries, including the U.S., Russia and Israel are interested in the company's proprietary discoveries, which center around protection of normal tissues from exposure to radiation and other stresses. Given the growing concern about Iran's nuclear capabilities, multi-million dollar orders for their product from neighboring countries make sense.

This is an article that was published in Israel, which discusses the company:

http://www.ynet.co.il/english/articles/0,7340,L-3748014,00.html

There was another good write up about the company here:

Time To Dote On Cleveland BioLabs' Radiation Antidote?

Our staff is preparing a special report and interview which will run in this space within the next 24 hours.

Disclosure: Long CBLI




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter